![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PHARMACOKINETIC INTERACTION BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND RITONAVIR-BOOSTED HIV-1 PROTEASE INHIBITORS ATAZANAVIR, LOPINAVIR, AND DARUNAVIR
|
|
|
Reported by Jules Levin
Presented at the 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, Washington, USA.
EGJ Hulskotte ,1 H-P Feng,2 F Xuan ,2 MGJA van Zutven,1* E O'Mara,2 S Youngberg,3 JA Wagner,2 JR Butterton 2
1Merck Sharp & Dohme Corp., The Netherlands; 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 3Celerion, Lincoln, NE, USA
![CROI1.gif](../images/030712/030712-6/CROI1.gif)
![CROI2.gif](../images/030712/030712-6/CROI2.gif)
![CROI3.gif](../images/030712/030712-6/CROI3.gif)
![CROI4.gif](../images/030712/030712-6/CROI4.gif)
![CROI5.gif](../images/030712/030712-6/CROI5.gif)
![CROI6.gif](../images/030712/030712-6/CROI6.gif)
![CROI7.gif](../images/030712/030712-6/CROI7.gif)
![CROI8.gif](../images/030712/030712-6/CROI8.gif)
![CROI9.gif](../images/030712/030712-6/CROI9.gif)
![CROI10.gif](../images/030712/030712-6/CROI10.gif)
![CROI11.gif](../images/030712/030712-6/CROI11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|